Literature DB >> 10232448

Physiological basis of improvement after lung volume reduction surgery for severe emphysema: where are we?

E Marchand1, G Gayan-Ramirez, P De Leyn, M Decramer.   

Abstract

Lung volume reduction surgery has become an accepted therapeutic option to relieve the symptoms of selected patients with severe emphysema. In a majority of these patients, it causes objective as well as subjective functional improvement. A proper understanding of the physiological determinants underlying these beneficial effects appears very important in order to better select patients for the procedure that is currently largely carried out on an empirical basis. Lung volume reduction surgery has two distinct effects. Firstly, it causes an increased elastic recoil, which at least partially explains the enhanced maximal expiratory flow. Secondly, it is associated with a reduction of hyperinflation which allows for an increase in global inspiratory muscle strength and in diaphragmatic contribution to tidal volume as well as a decrease in the inspiratory elastic load imposed by the chest wall. Taken together, these effects result in a reduced work of breathing and in an enhanced maximal ventilation which both contribute to the increased exercise capacity and reduced dyspnoea after surgery. The improved lung recoil and the reduced hyperinflation after volume reduction surgery were the primary postulates upon which the usual selection criteria for the procedure were based. It is now likely that these are correct. Nevertheless, some patients do not benefit from lung volume reduction surgery and the current literature does not allow for a refinement of the selection process from a physiological point of view. The exact mechanisms underlying the improvement in lung recoil, lung mechanics, and respiratory muscle function remain incompletely understood. Moreover, the effects of lung volume reduction surgery on gas exchange and pulmonary haemodynamics still need to be more fully investigated. An analysis of the characteristics of patients who do not benefit from the procedure and the development of an animal model for lung volume reduction surgery would probably help address these important issues.

Entities:  

Mesh:

Year:  1999        PMID: 10232448     DOI: 10.1183/09031936.99.13368699

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Lung volume reduction surgery.

Authors:  D M Geddes
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Aerosolized methacholine-induced bronchoconstriction and pulmonary hyperinflation in rats.

Authors:  Tetsuri Kondo; Toshimori Tanigaki; Chizuko Tsuji; Hiroshi Ishii; Gen Tazaki; Yuusuke Kondo
Journal:  J Physiol Sci       Date:  2009-06-09       Impact factor: 2.781

4.  The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Tae Rim Shin; Yeon-Mok Oh; Joo Hun Park; Keu Sung Lee; Sunghee Oh; Dae Ryoung Kang; Seungsoo Sheen; Joon Beom Seo; Kwang Ha Yoo; Ji-Hyun Lee; Tae-Hyung Kim; Seong Yong Lim; Ho Il Yoon; Chin Kook Rhee; Kang-Hyeon Choe; Jae Seung Lee; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

Review 5.  Pathogenesis of hyperinflation in chronic obstructive pulmonary disease.

Authors:  Philippe Gagnon; Jordan A Guenette; Daniel Langer; Louis Laviolette; Vincent Mainguy; François Maltais; Fernanda Ribeiro; Didier Saey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-02-15

6.  A Patient with GOLD Stage 3 COPD « cured » by One-Way Endobronchial Valves.

Authors:  Eric Marchand; Jean-Paul d'Odemont; Michael V Dupont
Journal:  Medicina (Kaunas)       Date:  2019-03-11       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.